Table 2:
The rate of change for each outcome by preclinical stages and by mutation status (N=142)*
| Markers | Asymptomatic Mutation carriers (N=81)~ | Mutation non-carriers (N=61)~ | ||||||
|---|---|---|---|---|---|---|---|---|
| EYO stage (−35, −13], Slope (SE), N=43 | EYO stage (−13, −7], Slope (SE), N=16 | EYO stage (−7, 0), Slope (SE), N=22 | Overall Preclinical Stage (−35, 0) | EYO stage (−35, −13], Slope (SE), N=32 | EYO stage (−13, −7], Slope (SE), N=12 | EYO stage (−7, 0), Slope (SE), N=17 | Overall Preclinical Stage (−35, 0) | |
| DIAN Cognitive Composite | 0.004(0.019) | −0.026 (0.033) | −0.13 (0.035) | −0.029 (0.016) | −0.01 (0.019) | −0.01 (0.035) | −0.02 (0.032) | −0.01 (0.02) |
| CSF Aβ42, pg/mL | −31.4 (9.8) | −33.2 (13.8) | −11.9 (10.7) | −25.2 (6.2) | −0.8 (10.7) | −9.4 (13.5) | −4.1 (15.0) | −4.4 (7.0) |
| CSF Total Tau, pg/mL | 1.9 (1.3) | 2.2 (1.8) | 4.1 (1.4) | 2.9 (0.8) | −0.1 (1.5) | 0.4 (1.8) | −0.8 (1.9) | −0.10 (0.98) |
| CSF Ptau, pg/mL | −1.9 (1.4) | 1.7 (2.0) | −1.7 (1.0) | −1.2 (0.8) | −0.5 (1.5) | −1.0 (1.9) | −3.0 (1.7) | −1.5 (1.1) |
| PIB PET Cortical SUVR | 0.065 (0.013) | 0.079 (0.024) | 0.094 (0.021) | 0.075 (0.010) | 0.001 (0.014) | −0.018 (0.028) | 0.016 (0.020) | 0.002 (0.01) |
| MRI Precuneus Thickness | −0.009 (0.008) | −0.019 (0.013) | −0.068 (0.013) | −0.025 (0.006) | −0.014 (0.008) | −0.014 (0.016) | 0.005 (0.013) | −0.010 (0.007) |
| MRI Total Hippocampal | −10.5 (19.2) | −37.6 (31.7) | −134.7 (30.6) | −43.4 (15.2) | −11.9 (20.6) | −0.18 (38.1) | −39.5 (32.2) | −16.4 (16.7) |
| FDG PET Cortical SUVR | 0.012 (0.007) | −0.029 (0.015) | −0.020 (0.012) | 0.0003 (0.006) | 0.013 (0.008) | 0.006 (0.014) | 0.008 (0.012) | 0.011 (0.006) |
*
Significant rates of change are in bold.
~
N varied slightly from marker to marker due to unbalanced missing data.